Stock listing
Drugs Made In America Acquisition Ii Corp.
Selected listing: DMII · NASDAQ · USD · US
Drugs Made In America Acquisition Ii Corp. (NASDAQ:DMII), Finance. Latest release May 14, 2026: Drugs Made In America Acquisition II Corp. 1Q 2026: Net income…
- Ticker
- NASDAQ:DMII
- Asset type
- Stock
- Sector
- Finance
- Industry
- Financial Conglomerates
- Exchange
- NASDAQ
- Currency
- USD
About Drugs Made In America Acquisition Ii Corp.
Drugs Made In America Acquisition II Corp. (ticker: DMII) is a public company operating in the American market. DMII aims to facilitate the production and distribution of drugs made in the United States.
Latest news from Drugs Made In America Acquisition Ii Corp.
Drugs Made In America Acquisition II Corp. 1Q 2026: Net income $4.34M, EPS $0.07— 10-Q Summary
May 14, 2026
Drugs Made In America Acquisition II 10-K: Net income $4.19M, Net loss $0.15M
April 15, 2026
Drugs Made In America Acquisition II Finalizes $1.4M Notes Deal, Adds $300K Interim Convertible
April 3, 2026
Drugs Made In America Acquisition II Secures $150,000 Convertible Bridge Note From Alpha Multi Family Office
March 17, 2026
Drugs Made In America appoints Roger Bendelac as CEO after Lynn Stockwell resignation
March 6, 2026
Research Drugs Made In America Acquisition Ii Corp.
Drugs Made In America Acquisition Ii Corp. company profile
View the public company page for Drugs Made In America Acquisition Ii Corp. on 6ix.
Drugs Made In America Acquisition Ii Corp. news
Read company news and market updates connected to Drugs Made In America Acquisition Ii Corp..
Drugs Made In America Acquisition Ii Corp. investor events
Find investor webinars, events, and replay context for Drugs Made In America Acquisition Ii Corp..